Janssen Pharms., Inc. v. Teva Pharms. USA, Inc. – Invega Sustenna® (Paliperidone Palmitate)

August 1, 2024

Case Name: Janssen Pharms., Inc. v. Teva Pharms. USA, Inc., No. 2022-1258, 2022-1307, 2024 WL 1355733 (Fed. Cir. Apr. 1, 2024) (Circuit Judges Dyk, Prost, and Hughes presiding; Opinion by Prost, J.) (Appeal from D.N.J., Cecchi, J.)….
By: Robins Kaplan LLP

Janssen Pharms., Inc. v. Teva Pharms. USA, Inc. – Invega Sustenna® (Paliperidone Palmitate)

How the Timing of Director Review May Affect Co-Pending Litigation

RegFi Episode 42: Beyond the Breach: The CISO’s Role as a Strategic Risk Manager